Aucta Pharmaceuticals is pleased to announce the late January launch of PYQUVI oral suspension 22.75 mg/mL. PYQUVI, a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) ...
Upregulated expression of transcription factors promoting cone identity in late-stage retinal progenitors drives development ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results